Form 4: Edwards Lifesciences Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Daniel J. Lippis, CVP, TAVR of Edwards Lifesciences Corp, sold 619 shares of common stock on August 11, 2026 for $92.03 per share.

Summary

  • Option exercise/conversion: acquired 619 Common Stock at $72.68 ($44,989) on August 11, 2026; holds 40,653 after (Direct).
  • Open-market sale: disposed of 619 Common Stock at $92.03 ($56,967) on August 11, 2026; holds 40,034 after (Direct).
  • Option exercise/conversion: disposed of 619 Employee Stock Option (Right to Acquire) on August 11, 2026; holds 4,333 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $56,967 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Daniel J. Lippis — Officer (CVP, TAVR)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-11Option exercise/conversionCommon Stock619$73$45.0K40,652.91
2026-08-11Open-market saleCommon Stock619$92$57.0K40,033.91
2026-08-11Option exercise/conversionEmployee Stock Option (Right to Acquire)619——4,333

Key Dates

DateDescription
2026-08-11Option exercise/conversion (619 shares)
2026-08-11Open-market sale (619 shares)
2026-08-11Option exercise/conversion (619 shares)

Keywords

insider transaction, Form 4, EW, Edwards Lifesciences Corp, bearish, Daniel J. Lippis

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.